A Differentiated Next Generation Protein Drug Conjugate for the Treatment of ROR1 Positive Tumours

Time: 1:50 pm
day: Track A - Day 1 PM


  • Novel ROR1 specific protein drug conjugates (PDCs) have been developed, based on small VNAR targeting domains,
    that offer potential improvements over conventional ADC approaches.
  • By exploiting a novel cleavable linker payload platform, a pre-clinical candidate has been identified which is highly efficacious in vivo in ROR1+ TNBC and other tumour models where it shows sustained and durable regressions.
  • The flexible formatting provided by our protein-based approach provides ready access to ROR1 targeting bispecific and bi-paratopic drug conjugates.